VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia

Am J Hematol. 2006 Dec;81(12):987-8. doi: 10.1002/ajh.20672.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Boronic Acids / administration & dosage*
  • Bortezomib
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Humans
  • Leukemia, Plasma Cell / blood
  • Leukemia, Plasma Cell / drug therapy*
  • Leukemia, Plasma Cell / pathology
  • Male
  • Middle Aged
  • Multiple Myeloma / blood
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / pathology
  • Neoplasms, Second Primary / blood
  • Neoplasms, Second Primary / drug therapy*
  • Neoplasms, Second Primary / pathology
  • Protease Inhibitors / administration & dosage*
  • Pyrazines / administration & dosage*
  • Remission Induction

Substances

  • Boronic Acids
  • Protease Inhibitors
  • Pyrazines
  • Bortezomib
  • Etoposide
  • Doxorubicin

Supplementary concepts

  • VAD combination